Trials / Unknown
UnknownNCT03047811
The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study of targeted NY-ESO-1 T cell receptor (TCR) genetic modified autologous T cells treatment of advanced solid tumors 1. The main purpose - security and ORR; 2. A secondary purpose - median progression-free surial;1 year, 2 years, total 5 years survival rate;The quality of life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | TCR - T cell therapy | Low dose group: 1 x 10 \^8 /kg T cell total reinfusion. High dose groups: 10 x 10 \^ 8 / kgT cell total reinfusion. |
Timeline
- Start date
- 2016-08-26
- Primary completion
- 2017-12-31
- Completion
- 2017-12-31
- First posted
- 2017-02-09
- Last updated
- 2017-02-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03047811. Inclusion in this directory is not an endorsement.